 The Healthcare products Regulatory Agency MHRA of the U.K. has granted Conditional Marketing Authorization for Valneva SEs NASDAQ: VALNCOVID-19 vaccine candidate, VLA2001, for primary immunization in adults 18 to 50 years of age. MHRA found that VLA2001 meets safety,. 